Erzhen Chen

Also affiliated with Sichuan University, Ruijin Hospital, West China Hospital of Sichuan University, Shanghai Institute of Hypertension

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment”.

COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.1765

N/A

0.425DataRank · unranked

16 citations

Yu Xu, Ruizhi Zheng, Lei Ye, Gang Lv, Zhujun Cao +26 more

Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system

Nature Communications(2024)10.1038/s41467-024-52258-w

N/A

0DataRank · unranked

38 citations

Marko Groeger, Aditi Sharma, Ishan Goswami, Erzhen Chen, Fenmiao Zhong +6 more